|
Press Releases |
|
|
|
Monday, August 16, 2021 |
|
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Launched in Japan for EZH2 Gene Mutation-Positive Follicular Lymphoma |
Eisai Co., Ltd. announced today that it has launched the anticancer agent EZH2 inhibitor "Tazverik Tablets 200 mg" (tazemetostat hydrobromide), in Japan with the indication of relapsed or refractory EZH2 gene mutation-positive follicular lymphoma (only when standard treatment is not applicable). more info >> |
|
Thursday, August 12, 2021 |
|
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for First-Line Treatment of Adult Patients with Advanced Renal Cell Carcinoma (RCC) |
Eisai and Merck & Co., Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
Thursday, August 5, 2021 |
|
Eisai Receives Award for Excellence in Corporate Communications at the 37th Corporate Communications Awards |
Eisai Co., Ltd. announced today that it has received the Award for Excellence in Corporate Communications at the 37th annual Corporate Communications Awards, hosted by the Japan Institute for Social and Economic Affairs, an affiliate of the Japanese Business Federation (Tokyo). more info >> |
|
Monday, August 2, 2021 |
|
Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures |
Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for partial onset seizures in patients with epilepsy 4 years of age and older" in China from the National Medical Products Administration. more info >> |
|
Friday, July 30, 2021 |
|
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401) |
Eisai Co., Ltd. and Biogen Inc. today announced results of a longitudinal preliminary assessment of the clinical effects of lecanemab (development code: BAN2401) -- granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) in June 2021. more info >> |
|
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer's Disease at AAIC 2021 |
Biogen and Eisai Co., Ltd. today announced that Biogen led a late-breaking presentation on the design of the first real-world observational Phase 4 study in Alzheimer's disease called ICARE AD-US, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
Thursday, July 29, 2021 |
|
Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment |
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 20th consecutive year since its initial inclusion in 2002. more info >> |
|
Tuesday, July 27, 2021 |
|
Biogen and Eisai Announce ADUHELM (aducanumab-avwa) Data Presentations at Alzheimer's Association International Conference 2021 |
Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen, as part of its Alzheimer's disease (AD) research portfolio, will contribute four virtual posters that showcase data from its clinical trials with ADUHELMTM (aducanumab-avwa) injection 100 mg/mL solution at the AAIC. more info >> |
|
Friday, July 23, 2021 |
|
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma |
Study Results Demonstrated Statistically Significant Improvements in Overall Survival, Progression-Free Survival and Overall Response Rate, Helping to Address a Significant Unmet Need in Advanced Endometrial Carcinoma. more info >> |
|
Wednesday, July 21, 2021 |
|
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021 |
Eisai Co., Ltd. announced today that the company will conduct a total of 11 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401) for which the U.S. Food and Drug Administration has granted Breakthrough Therapy designation, at the Alzheimer's Association International Conference (AAIC). more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 18:00 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
|
|
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
May 16, 2024 22:00 HKT/SGT
|
|
|
DEXIS Innovation Continues With New DEXIS Ti2 Sensor as Successor to the DEXIS Titanium Sensor, the #1 Selling Intraoral Sensor in the United States
May 16, 2024 21:30 HKT/SGT
|
|
|
Horus: Million Dollar Air-Mail NFT Drop on Base
May 16, 2024 20:11 HKT/SGT
|
|
|
HKTDC kicks off third International Healthcare Week
May 16, 2024 18:00 HKT/SGT
|
|
|
CleverTap's 2024 Market Research Report Unveils that Brands Implementing Higher AI Adoption See 4x Boost in Conversions
May 16, 2024 17:00 HKT/SGT
|
|
|
Q2 Metals Announces Re-Assay Results and Spring 2024 Exploration Plan for Cisco Lithium Property, James Bay Territory, Quebec, Canada
May 16, 2024 15:09 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|